Evaluation of safety and immunogenicity of hepatitis E vaccine in maintenance hemodialysis patients.
10.3760/cma.j.cn112150-20220223-00168
- Author:
Xue Lian WANG
1
;
Yan Ting LI
2
;
Xin Jing MA
3
;
Yi Sheng LING
2
;
Ting WU
3
;
Jian Jun NIU
2
Author Information
1. Hospital Infection Management Department,Xiamen Cardiovascular Hospital,Xiamen University,Xiamen 361008, China.
2. Xiamen Zhong Shan Hospital, Xiamen University, Xiamen 361004, China.
3. School of Public Health, Xiamen University, Xiamen 361102, China.
- Publication Type:Journal Article
- MeSH:
Clinical Trials, Phase III as Topic;
Female;
Hepatitis E;
Humans;
Immunogenicity, Vaccine;
Immunoglobulin G;
Male;
Renal Dialysis;
Viral Hepatitis Vaccines/adverse effects*
- From:
Chinese Journal of Preventive Medicine
2022;56(4):464-467
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the safety and immunogenicity of hepatitis E vaccine(HEV)in Maintenance hemodialysis(MHD)patients. Methods: Based on an open-labeled controlled trial, from May 2016 to March 2018, 35 eligible MHD patients were recruited in the Hemodialysis Center of Zhongshan Hospital Affiliated to Xiamen University as the experimental group, and 70 MHD patients with matched age, gender and underlying diseases as the control group. The experimental group received HEV at 0, 1 and 6 months according to the standard vaccination procedures, while the control group received routine diagnosis and treatment without vaccine and placebo injection to observe the safety and immunogenicity of the vaccine. The safety of vaccine in MHD population was evaluated by the incidence of adverse reactions/events in the experimental and control groups. The immunogenicity of HEV in MHD patients was evaluated by comparing the data from the phase Ⅲ clinical trial. Results: The overall incidence of adverse reactions/events was 17.1% (18/105), and there were no grade 3-4 adverse reactions/events related to vaccination. In the experimental group, the incidence of local adverse reactions/events was 20.0% (7/35), and the incidence of systemic adverse reactions/events was 17.1% (6/35).There was no significant difference in the incidence of systemic adverse reactions/events between the experimental group and the control group (P>0.05). There were 23 patients receiving 3 doses with the standard schedule. The positive rate of HEV-IgG antibody was 100% and the GMC was 14.47(95%CI:13.14-15.80) WU/ml, which showed no significant difference compared with the 46 patients in Phase Ⅲ clinical trial (t=-1.04, P>0.05). Conclusion: Recombinant HEV has good safety and immunogenicity in MHD patients.
